Back

Contextualising outcomes behind activin signaling inhibitor in pulmonary arterial hypertension - discussion and Q&A

29 August 2026 (15:50 - 16:00)
Organised by: Logo
Congress Presentation Part of: Contextualising outcomes behind activin signaling inhibitor in pulmonary arterial hypertension Pulmonary Hypertension Open Access ESC Congress 2026 European Society of Cardiology

4 More presentations in this session

Presentation thumbnail
Effects of activin signaling inhibitor on afterload, right ventricular function, and structure: a 3-prong view
Doctor A. Vaidya (Temple, US)
Presentation thumbnail
Disentangling the central, peripheral, and haematological mechanisms of benefit of activin signaling inhibitor on exercise performance in pulmonary arterial hypertension
Assistant Professor Y. Reddy (Rochester, US)
Presentation thumbnail
Haemodynamic parameters as part of risk assessment in pulmonary arterial hypertension: does cardiac output matter?
Doctor A. Boucly (Le Kremlin Bicetre, FR)
Presentation thumbnail
Activin signaling inhibitor: from clinical outcomes to physiologic understanding
Doctor T. Cascino (Ann Arbor, US)

Access the full session

Session thumbnail
Contextualising outcomes behind activin signaling inhibitor in pulmonary arterial hypertension

The Event

Event poster

ESC Congress 2026

29 August 2026 15:50 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources